The Relation Between Type 2 Diabetes Mellitus and Parkinson Disease Up to Date

Open access

Abstract

Parkinson’s disease is defined nowadays as a neurodegenerative disease with prominent motor symptoms accompanied by a wide range of comorbidities, some of them, like type 2 diabetes mellitus, probably implicated in the pathogenesis and progression of the disease. In order to achieve this article, which aimed to realize an up to date synthesis of published dedicated papers, a PubMed search was performed; it revealed increasing evidence that these two morbid conditions share many pathogenic pathways and current studies are trying to finally transform the accumulated knowledge into curative therapy or effective prevention for these frequent and complex diseases.

1. Santiago JA, Bottero V, Potashkin JA. Biological and Clinical Implications of Comorbidities in Parkinson’s Disease. Front Aging Neurosci, 2017

2. Todorova A, Jenner P, Chaudhuri KJ. Non-motor Parkinson’s: integral to motor Parkinson’s, yet often neglected. Practical Neurology 14(5): 310–322, 2014

3. Geng X, Lou H, Wang J et al. α-Synuclein binds the K(ATP) channel at insulin-secretory granules and inhibits insulin secretion. Am J Physiol Endocrinol Metab 300: 276–286, 2011.

4. Vidal-Martinez G, Yang B, Medrano J, Perez RG. Could α-Synuclein Modulation of Insulin and Dopamine Identify a Novel Link Between Parkinson’s Disease and Diabetes as Well as Potential Therapies? Front Mol Neurosci, 2018

5. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson’s disease, insulin resistance and novel agents of neuroprotection. Brain136: 374–384, 2013

6. Sulzer D, Cragg SJ, Rice ME. Striatal dopamine neurotransmission: regulation of release and uptake. Basal Ganglia 6: 123–148, 2016

7. Stouffer MA, Woods CA, Patel JC et al. Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward. Nat Commun 6: 8543, 2015.

8. Santiago JA, Potashkin JA. Integrative network analysis unveils convergent molecular pathways in Parkinson’s disease and diabetes. PLoS One 8(12): e83940, 2013

9. Santiago JA, Potashkin JA. Shared dysregulated pathways lead to Parkinson’s disease and diabetes. Trends Mol Med 19: 176–186, 2013

10. Ciaramella A, Salani F, Bizzoni F et al. Blood dendritic cell frequency declines in idiopathic Parkinson’s disease and is associated with motor symptom severity. PLoS One 8(6): e65352, 2013.

11. Li XY, Teng JJ, Liu Y, Wu YB, Zheng Y, Xie AM. Association of AKT1 gene polymorphisms with sporadic Parkinson’s disease in Chinese Han population. Neurosci Lett 629: 38–42, 2016

12. Banks WA, Owen JB, Erikson MA. Insulin in the brain: there and back again. Pharmacol Ther 136(1): 82-93, 2012

13. Ahmed RM, Irish M, Piguet O, Halliday GM, Ittner LM, Farooqi S. Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behavior and metabolism. The Lancet 15(3): 332-342, 2016

14. Yang YW, Hsieh TF, Li CI et al. Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine 96: e5921, 2017

15. Yue X, Li H, Yan H, Zhang P, Chang L, Li T. Risk of parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies. Medicine 95: e3549, 2016

16. Sun Y, Chang YH, Chen HF, Su YH, Su HF, Li CY. Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care 35: 1047–1049, 2012

17. Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. Diabetes and the risk of developing Parkinson’s disease in Denmark. Diabetes Care 34: 1102–1108, 2011

18. Xu Q, Park Y, Huang X et al. Diabetes and risk of Parkinson’s disease. Diabetes Care 34(4): 910–915, 2011

19. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care 30(4): 842–847, 2007

20. Driver JA, Smith A, Buring JE, Gaziano JM, Kurth T, Logroscino G. Prospective cohort study of type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care 31(10): 2003–2005, 2008

21. Bosco D, Plastino M, Cristiano D et al. Dementia is associated with insulin resistance in patients with Parkinson’s disease. J Neurol Sci 315(1-2): 39–43, 2012

22. Lu L, Fu DL, Li HQ, Liu AJ, Li JH, Zheng GQ. Diabetes and risk of Parkinson’s disease: an updated meta-analysis of case-control studies. PLoS One 9(1): e85781, 2014

23. De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT. Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology 91(2): e139-e142, 2018

24. Santos García D, Suárez Castro E, Expósito I et al. Comorbid conditions associated with Parkinson’s disease: a longitudinal and comparative study with Alzheimer disease and control subjects. J Neurol Sci 373: 210–215, 2017

25. Perju-Dumbrava L, Muntean ML, Muresanu DF. Cerebrovascular Profile Assessment in Parkinson's Disease Patients. CNS Neurol Disord Drug Targets 13(4): 712-716, 2014

26. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3): 181-184, 1992

27. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord 19(11): 1306-12, 2004

28. Bohnen NI, Kotagal V, Müller ML et al. Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord 20(12): 1394–1398, 2014

29. Kotagal V, Albin RL, Müller ML, Koeppe RA, Frey KA, Bohnen NI. Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord 19(5): 522–526, 2013

30. Cereda E, Barichella M, Cassani E, Caccialanza R, Pezzoli G. Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology 78(19): 1507–1511, 2012

31. Pagano G, Polychronis S, Wilson H et al. Diabetes mellitus and Parkinson disease. Neurolog 90(19): e1654-e1662, 2018

32. Santiago JA, Potashkin JA. Blood biomarkers associated with cognitive decline in early stage and drug-naive Parkinson’s disease patients. PLoS One 10: e0142582, 2015

33. Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson’s disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord 18(6): 753–758, 2012

34. Athauda D, Wyse R, Brundin P, Foltynie T. Is exenatide a treatment for Parkinson’s disease? J Parkinsons Dis 7(3): 451–458, 2017

35. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J Parkinsons Dis 4(3): 337–344, 2014

36. Brauer R, Bhaskaran K, Chaturvedi N, Dexter DT, Smeeth L, Douglas I. Glitazone treatment and incidence of Parkinson’s disease among people with diabetes: a retrospective cohort study. PLoS Med 12(7): e1001854, 2015

Romanian Journal of Diabetes Nutrition and Metabolic Diseases

The Journal of Romanian Society of Diabetes Nutrition and Metabolic Diseases

Journal Information


CiteScore 2018: 0.19

SCImago Journal Rank (SJR) 2018: 0.128
Source Normalized Impact per Paper (SNIP) 2018: 0.229

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 81 81 17
PDF Downloads 62 62 13